Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE EFFECT OF NEDOCROMIL SODIUM ON CHILDHOOD ASTHMA DURING THE VIRAL SEASON
Autore:
KONIG P; EIGEN H; ELLIS MH; ELLIS E; BLAKE K; GELLER D; SHAPIRO G; WELCH M; SCOTT C;
Indirizzi:
UNIV MISSOURI,HLTH SCI CTR,DEPT CHILD HLTH,DIV PULM ALLERGY COLUMBIA MO 65212 JAMES WHITCOMB RILEY HOSP CHILDREN,DEPT PEDIAT,PULM SECT INDIANAPOLISIN 46202 CHILDRENS HOSP ORANGE CTY ORANGE CA 92668 MURO PHARMACEUT INC TEWKSBURY MA 00000 NEMOURS CHILDRENS CLIN JACKSONVILLE FL 00000 ALL CHILDRENS HOSP ST PETERSBURG RUSSIA NW ASTHMA & ALLERGY CTR SEATTLE WA 00000 ALLERGY & ASTHMA MED GRP & RES CTR SAN DIEGO CA 92123 FISONS PHARMACEUT INC ROCHESTER NY 00000
Titolo Testata:
American journal of respiratory and critical care medicine
fascicolo: 6, volume: 152, anno: 1995,
pagine: 1879 - 1886
SICI:
1073-449X(1995)152:6<1879:TEONSO>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
RESPIRATORY-TRACT INFECTIONS; PRESCHOOL-CHILDREN; AIRWAY REACTIVITY; INHALED STEROIDS; DOUBLE-BLIND; IGE LEVELS; PRECIPITANTS; VIRUSES; HYPERREACTIVITY; EXACERBATIONS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
46
Recensione:
Indirizzi per estratti:
Citazione:
P. Konig et al., "THE EFFECT OF NEDOCROMIL SODIUM ON CHILDHOOD ASTHMA DURING THE VIRAL SEASON", American journal of respiratory and critical care medicine, 152(6), 1995, pp. 1879-1886

Abstract

Viral-induced symptomatic respiratory infections (SRI) frequently cause exacerbations of asthma in children. This study investigated the protective effects of 0.5% nedocromil sodium nebulizer solution given three times a day in preventing asthma exacerbations associated with SRI. Ninety-three mild-moderate asthmatic children (6 to 12 yr of age) received either 0.5% nedocromil sodium or placebo for 24 wk during the viral season. The nedocromil sodium group was symptom-free 58% of the days, and the placebo-treated patients were symptom-free 45% of the days (p = 0.027). During Weeks 1-12, significant differences favored nedocromil sodium for asthma summary score (means: nedocromil sodium = 0.61, placebo = 0.92; p = 0.026), and daytime asthma (nedocromil sodium =0.78, placebo = 1.22; p = 0.03). Significant differences were noted during monthly intervals for cough (Weeks 1-4: nedocromil sodium = 0.61, placebo = 0.92, p = 0.027) and peak expiratory flow rate (PEFR) (nedocromil sodium 262, placebo = 254 L/min, p = 0.041 Weeks 9-12). Patients in the active treatment group reduced their need for rescue inhaledbeta(2)-agonist by 10%, whereas patients treated with placebo demonstrated a 24% increase. There was a strong correlation between asthma symptoms and SRI symptoms (r = 0.47; p < 0.001). During SRIs, patients in the nedocromil sodium group demonstrated more rapid resolution of asthma symptoms immediately following infection (p = 0.033 summary score, p = 0.039 sleep difficulty). No serious adverse events were noted. Nedocromil sodium did not prevent the infection or exacerbation of asthma symptoms during SRI. However, patients treated with nedocromil sodium had improved overall asthma control during the viral season and faster resolution of asthma symptoms following infection.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/10/20 alle ore 11:25:43